iron sucrose - Profile

What are the generic drug sources for iron sucrose and what is the scope of freedom to operate?

Iron sucrose is the generic ingredient in two branded drugs marketed by Intl Medication Sys, Mylan Labs Ltd, Sandoz, and Am Regent, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Summary for iron sucrose

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4

US Patents and Regulatory Information for iron sucrose

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intl Medication Sys	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	208977-001	Aug 8, 2025	AB	RX	No	No
Intl Medication Sys	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	208977-002	Aug 8, 2025	AB	RX	No	No
Intl Medication Sys	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	208977-003	Aug 8, 2025	AB	RX	No	No
Mylan Labs Ltd	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	212559-001	Aug 8, 2025	AB	RX	No	No

IRON SUCROSE (IV iron) Investment Scenario and Fundamentals: Patent/Exclusivity Snapshot, Generic and Biosimilar Threats, and Revenue Risk Map

Last updated: July 22, 2026

Iron sucrose is an established intravenous (IV) iron for iron deficiency anemia (IDA) in adults, including chronic kidney disease (CKD) and inflammatory states. The economic thesis for “iron sucrose” products is driven less by brand-specific patent exclusivity and more by (1) formulary penetration across US hospital networks, (2) IV iron supply chain reliability and pharmacovigilance performance, (3) payor contracting dynamics versus newer IV irons (ferric carboxymaltose, ferric derisomaltose, ferumoxytol), and (4) utilization patterns tied to dose scheduling and administration time.

Below is an IP and regulatory fundamentals view designed for investment, licensing, and launch risk.

---

What patents protect iron sucrose (IV) and how strong is the patent estate?

Executive answer: For “iron sucrose” as an active ingredient, the key commercial risk is not an active ingredient primary patent barrier. The market is largely supply-and-formulation competitive, with the practical patent landscape dominated by product-specific composition/presentation patents (e.g., concentration, container closure, manufacturing, stability, and process improvements) rather than exclusive platform coverage on iron sucrose itself.

How to think about iron sucrose IP in practice

Iron sucrose is a longstanding commodity active with widespread generic availability. Investment-grade IP diligence typically focuses on:

• Drug product patents tied to specific labeled presentations (dose strength, pack configuration, container type).
• Manufacturing process patents (purification, crystallization/solubilization controls, particle size/colloid stability targets).
• Stability and shelf-life patents (freeze-thaw handling, oxidation control, expiration extension).
• Methods of use that map to subsets of labeled populations (CKD/non-CKD, pregnancy-related dosing regimens where applicable in labeling).

Investment implication: In most deals for iron sucrose, returns hinge on differentiation that survives substitution, such as demonstrated equivalence, lower total administration time, favorable contracting, or fewer adverse event signals in routine use, rather than long-duration exclusion by a single core patent.

What this means for valuation

• Brand-like margins are limited where payors treat IV iron products as interchangeable within therapeutic categories.
• Sustainable pricing power depends on contracting strength and hospital procurement inertia.
• Litigation-driven protection is usually lower probability than in newer specialty injectables, unless the target company has a specific, late-expiring product or manufacturing patent bundle.

---

When does iron sucrose lose exclusivity, and what does that mean for generic entry timing?

Executive answer: Iron sucrose lacks a meaningful active-ingredient exclusivity wall at the US level for investors making generic/launch assumptions. The practical timing risk comes from abbreviated approval pathways, existing market authorizations, and any product-specific remaining IP.

US exclusivity mechanics investors should model

Even without strong active-ingredient protection, two forces affect entry timing:

1. Patent barriers listed (or omitted) against the reference listed drug (RLD) in the Orange Book.
2. Five-year new chemical entity (NCE) or three-year new clinical investigation (NCI) exclusivities are not the main driver for iron sucrose, given its maturity as an active.
3. Later regulatory supplements can sometimes create new exclusivity for specific labeling or manufacturing changes, but this is atypical for commodity-like products.

Investment implication: Use a “patent-by-presentation” model. Treat exclusivity as a moving target based on container/strength/manufacturing patents, not on a single “iron sucrose” expiration date.

---

What is the Orange Book status of iron sucrose products?

Executive answer: The Orange Book typically lists patents by RLD tied to each marketed presentation. For commodity injectables, a pattern is common: multiple product and process patents may be listed, but many are expired or irrelevant to a given applicant’s proposed formulation.

How to use Orange Book listings in diligence

For a licensing or investment decision, the actionable steps are:

• Map each relevant RLD (by strength and NDA holder) to listed patents.
• Identify which patents are still within term and which are “method” vs “composition/process” vs “use”.
• For each patent, align your contemplated ANDA filing strategy to whether it can be designed around the protected subject matter.

Investment implication: If the target product’s remaining patents are narrow (process or stability) they may not provide robust revenue protection against “design around” manufacturing. If the portfolio includes broader product composition/presentation barriers that are difficult to engineer around, the risk profile improves.

---

What generic entry risks exist for iron sucrose in the US?

Executive answer: The entry risks are structural and commercial rather than patent-limited. Commodity supply chains, regulatory interchangeability, and hospital procurement practices increase generic substitution likelihood.

Key generic risks

• Therapeutic class substitution: Hospitals and ID/renal formularies frequently switch across IV iron products based on contracting and administration practicality.
• Batch-to-batch consistency: If an entrant has stability or quality drift signals, uptake may slow. If the entrant meets equivalence and supply reliability, uptake can be fast.
• Procurement contracting: Group purchasing organizations and health system formularies often award on price and reliability, compressing margin opportunity.

Where “patent risk” still matters

Even for commodity actives, generic entry can be slowed by:

• Pending or active injunction threats if specific patents are asserted and noninfringement is disputed.
• Special labeled dosing regimens where a method-of-use patent blocks a narrow population statement (less common for iron sucrose than for branded biologics, but possible for product-specific claims).

---

How does iron sucrose compare with ferric carboxymaltose, ferric derisomaltose, and ferumoxytol for contracting and adoption?

Executive answer: The competitive set is defined by the IV iron category. Investors should model share shifts based on payer and provider preference for dosing convenience (reduced number of infusions), cost per treated course, and adverse event profile in routine practice.

Competitive dynamics investors should quantify

• Dosing convenience: Products that allow larger single doses with fewer visits may gain adoption if protocols permit.
• Safety profile and monitoring burden: Real-world incidence of hypophosphatemia (more linked to some newer agents), hypotensive reactions, and infusion-related events affects protocol choice.
• Renal and inpatient protocols: CKD and dialysis centers often have established pathways and procurement.

Investment implication

Iron sucrose can still be a core formulary product where dosing schedules align with protocol and cost contracting. But revenue growth is constrained if newer IV irons win by dosing convenience or payer rebates.

---

What patent litigation affects iron sucrose products, and how could settlements change market share?

Executive answer: For iron sucrose, litigation is generally not the central market driver compared with newer, patent-protected biologics. However, product-specific patents and method-of-use or manufacturing claims can still trigger ANDA litigation that affects timing.

What to model in a litigation-driven scenario

• Paragraph IV timelines: If a generic challenges listed patents, settlement can include an agreed launch date delay.
• Injunction risk: Courts can impose or deny injunction based on validity and infringement.
• Settlement terms: Settlement agreements sometimes include licensing, market share commitments, or supply arrangements.

Investment implication: In iron sucrose, litigation impact tends to be narrower and shorter than for high-value oncology or rare disease assets, but it can still determine a specific competitor’s first-year share trajectory.

---

How is iron sucrose regulated in the US (FDA pathway), and what does that mean for approval timelines?

Executive answer: Iron sucrose products are typically approved via abbreviated pathways for generics where bioequivalence and chemistry/manufacturing controls support equivalence. Approval timing is driven by ANDA completeness, facility inspections, and CMC demonstration rather than clinical program size.

What investors should watch

• CMC comparability: Colloidal/complex stability and particle characteristics are scrutinized.
• Container closure and dosing accuracy: IV iron products are sensitive to formulation stability and dilution behavior.
• Labeling: Key is whether labeling matches substitution expectations in hospital formularies.

Investment implication: For new entrants, timelines are more “CMC and inspection risk” than “phase 3 clinical risk.” That favors faster competitive entry but also increases quality system risk and potential post-approval changes.

---

How many patents cover iron sucrose, and how should investors map them to barriers?

Executive answer: Rather than a single monolithic estate, investors should assume a portfolio with:

• multiple product presentation listings,
• multiple process and stability patents,
• potentially some method-of-use claims tied to labeled regimens.

How to structure the mapping for decisioning

Create a barrier matrix per NDA/RLD:

• Patent number
• Expiration date
• Claim type (composition, process, use, stability)
• Scope summary (what must be avoided or designed around)
• Enforcement history (if any)
• Geographic scope (US focus; EU/UK depends on local filings)

Investment implication: Revenue protection is strongest when remaining patents cover claim elements that are difficult to reproduce without infringement (e.g., specific composition/process parameters that are tightly constrained). It weakens when claims are narrow and design-arounds exist.

---

What formulation patents protect iron sucrose, and what are the main design-around routes?

Executive answer: Formulation protection in iron sucrose tends to be tied to stability and manufacturing/process controls, because iron sucrose itself is a known entity. Design-arounds are commonly based on:

• different purification or processing steps,
• alternative control strategies meeting the same quality specifications,
• changes that preserve stability and dilution performance within regulatory specs.

Design-around risk profile for entrants

• If asserted patents claim a specific manufacturing parameter set, an entrant can sometimes meet comparable specs while using different process conditions.
• If patents claim stability outcomes with defined parameter thresholds that are hard to demonstrate identically, litigation risk rises.

Investment implication: Evaluate whether remaining patents are “how it’s made” versus “what it is.” The former is more often design-aroundable, the latter is more often exclusionary.

---

What is the biosimilar risk for iron sucrose?

Executive answer: Biosimilar frameworks do not apply in the same way as for biologics. Iron sucrose is a small-molecule/complex drug substance with generic substitution rather than biosimilar pathways.

Investment implication: Treat “biosimilar risk” as not applicable; focus on generic ANDA competition and formulation/process patent barriers.

---

Which companies are likely competitors for iron sucrose, and what market positioning matters?

Executive answer: Competition centers on established generic IV iron manufacturers and branded/legacy suppliers that maintain hospital contracts. The investor lens should prioritize companies with:

• strong sterile injectables track record,
• reliable production capacity for IV iron,
• documented pharmacovigilance handling and batch consistency.

Commercial positioning factors

• Tender wins in large health systems
• Contracting rebates and group purchasing arrangements
• Availability and lead times
• Discounting versus newer IV iron competitors

---

Revenue exposure: what drives demand for iron sucrose and where are the downside risks?

Executive answer: Demand for IV iron is driven by anemia prevalence in at-risk populations and by the hospital’s IV iron protocol. Revenue downside comes from protocol switches to newer agents, procurement price pressure, and supply interruptions.

Demand drivers

• CKD anemia management protocols
• Hospital inpatient anemia pathways
• Iron deficiency in inflammatory states

Downside risks to model

• Protocol shift to alternatives that reduce infusion burden
• Aggressive pricing from multiple generic entrants
• Supply chain constraints that cause stockouts and lead to temporary protocol switching
• Quality events and recalls that reduce formulary trust

---

Key Takeaways

• IP barrier is likely presentation- and process-specific, not active-ingredient exclusivity, for iron sucrose. Investors should model patent barriers at the RLD and presentation level.
• Generic competition risk is structural: hospital formularies and procurement mechanics push rapid substitution once regulatory approvals and quality controls are in place.
• Competitive pressure is dominated by other IV iron agents (dose convenience, protocol fit, and contracted pricing), which can move share even without patent challenges.
• Regulatory timelines favor entrants with strong CMC execution, making “launch speed” a function of manufacturability and inspection outcomes more than clinical trial risk.
• Litigation, if it occurs, is typically narrower and more likely to affect timing around specific products rather than maintain broad long-term exclusivity.

---

FAQs

1) How do patent expiration dates affect iron sucrose revenues versus generic competition?
Patent expiration affects incremental entry timing only when remaining patents are broad and difficult to design around; otherwise, procurement and category substitution determine revenues.

2) Do method-of-use patents matter for iron sucrose compared with composition/process patents?
They can matter for narrow labeled regimens, but category-level protocol switching often dilutes exclusivity unless method claims cover a high-uptake patient subset.

3) What CMC issues most often block generic IV iron approvals?
Stability, batch consistency, and demonstration that the approved product matches reference performance characteristics in real administration conditions.

4) Can supply reliability outweigh patent barriers in iron sucrose markets?
Yes. Stockouts shift clinicians to available IV iron options, and procurement can lock in new suppliers after shortages.

5) What’s the best investment proxy for future share in IV iron beyond patent status?
Hospital formulary placement, contract pricing over a typical treated-course basis, and demonstrated supply continuity.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drugs@FDA. U.S. Food and Drug Administration.
3. FDA. Abbreviated New Drug Applications (ANDAs). U.S. Food and Drug Administration.